 |
148 Diseases |  |
56 Trials |
|
56 Trials |  |
3630 News |  |
| «12...29303132333435363738394041 |
- Januvia (sitagliptin) / Merck (MSD)
New P1 trial, Combination therapy: A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients (clinicaltrials.gov) - Mar 28, 2012
P1, N=3, Terminated, Sponsor: Institut National de la Sant
- Diamyd (recombinant 65 kDa isoform of human glutamic acid decarboxylase) / Diamyd Medical, Januvia (sitagliptin) / Merck (MSD)
Trial termination, Immunomodulating: Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes (clinicaltrials.gov) - Mar 19, 2012
P2, N=7, Terminated, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed --> Terminated; Changes to study personnel.
- Januvia (sitagliptin) / Merck (MSD)
New P3 trial: Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation (clinicaltrials.gov) - Mar 11, 2012
P3, N=36, Recruiting, Sponsor: Washington University School of Medicine
- ||||||| Januvia (sitagliptin) / Merck (MSD)
Monotherapy: Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) (clinicaltrials.gov) - Mar 8, 2012
P3, N=653, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Changes to study personnel. Active, not recruiting --> Completed
- || fasiglifam (TAK-875) / Takeda
New P3 trial, Combination therapy: Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes (clinicaltrials.gov) - Mar 7, 2012
P3, N=916, Terminated, Sponsor: Takeda
- || Janumet (metformin/sitagliptin) / Merck (MSD), Januvia (sitagliptin) / Merck (MSD)
New P3 trial, Monotherapy: Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136) (clinicaltrials.gov) - Mar 4, 2012
P3, N=337, Completed, Sponsor: Merck
- |||||| Januvia (sitagliptin) / Merck (MSD)
Enrollment open: Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (clinicaltrials.gov) - Feb 22, 2012
P3, N=170, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Januvia (sitagliptin) / Merck (MSD)
Trial completion, Combination therapy: A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229) (clinicaltrials.gov) - Feb 19, 2012
P3, N=427, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
New P4 trial: Sitagliptin Dose Determination Study (clinicaltrials.gov) - Feb 7, 2012
P4, N=30, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- |||||||||| Suiny (anagliptin) / Kowa, Suzuken, Januvia (sitagliptin) / Merck (MSD)
New P3 trial: Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (clinicaltrials.gov) - Feb 7, 2012
P3, N=200, Active, not recruiting, Sponsor: JW Pharmaceutical
- Januvia (sitagliptin) / Merck (MSD)
Trial initiation date: Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin (clinicaltrials.gov) - Jan 31, 2012
P4, N=440, Active, not recruiting, Sponsor: Jothydev's Diabetes and Research Centre
Active, not recruiting --> Completed Initiation date: Sep 2011 --> Feb 2012
- | Inpefa (sotagliflozin) / Lexicon Pharma
Trial completion: A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia (clinicaltrials.gov) - Jan 25, 2012
P1, N=18, Completed, Sponsor: Lexicon Pharmaceuticals
Initiation date: Sep 2011 --> Feb 2012 Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
New P3 trial: MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jan 23, 2012
P3, N=0, Completed, Sponsor: Ono Pharmaceutical Co. Ltd
- | Januvia (sitagliptin) / Merck (MSD)
Enrollment change: Beta-Cell Function and Sitagliptin Trial (BEST) (clinicaltrials.gov) - Dec 27, 2011
P2, N=21, Completed, Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Active, not recruiting --> Completed N=45 --> 21
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion: Beta-Cell Function and Sitagliptin Trial (BEST) (clinicaltrials.gov) - Dec 27, 2011
P2, N=21, Completed, Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
N=45 --> 21 Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
New P4 trial: Effects of vildagliptin twice daily vs. sitagliptin once daily on reduction of oxidative stress and inflammation by blunting interprandial acute glucose fluctuations in patients with type 2 diabetes - PROBE Design (Multicenter Prospective, Randomized, Open-label parallel group with a blinded-endpoint) Effetti di vildagliptin(50 mg x 2/die) vs sitagliptin (100 mg/die) sullo stress ossidativo e sull'infiammazione in relazione alle fluttuazioni glicemiche interprandiali in pazienti con diabete mellito tipo 2 - PROBE Design (Multicenter Prospective, Randomized, Open-label parallel group with a blinded-endpoint) (EUDRACT) - Dec 26, 2011
P4, N=90, Ongoing, Sponsor: AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA' DEGLI STUDI DI NAPOLI
- |||||||||| Januvia (sitagliptin) / Merck (MSD)
New P3 trial: Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (clinicaltrials.gov) - Dec 1, 2011
P3, N=170, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| PF-04937319 / Pfizer, PegBio
New P2 trial: Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes (clinicaltrials.gov) - Nov 17, 2011
P2, N=345, Completed, Sponsor: Pfizer
- |||||||||| Januvia (sitagliptin) / Merck (MSD)
New P3 trial, Combination therapy: Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260) (clinicaltrials.gov) - Oct 27, 2011
P3, N=660, Completed, Sponsor: Merck Sharp & Dohme Corp.
- exenatide DUROS subcutaneous delivery system (ITCA 650) / Servier, i20 Therap
New P3 trial: A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Oct 18, 2011
P3, N=0, Withdrawn, Sponsor: Intarcia Therapeutics
- |||||||||| exenatide DUROS subcutaneous delivery system (ITCA 650) / Servier, i20 Therap
New P3 trial: A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Oct 18, 2011
P3, N=500, Recruiting, Sponsor: Intarcia Therapeutics
- ||||||| Januvia (sitagliptin) / Merck (MSD), taspoglutide (BIM51077) / Ipsen
Trial completion: A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. (clinicaltrials.gov) - Oct 16, 2011
P3, N=666, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion: Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 2, 2011
P1, N=24, Completed, Sponsor: Ludwig-Maximilians - University of Munich
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Januvia (sitagliptin) / Merck (MSD)
Clinical: Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) (clinicaltrials.gov) - Sep 29, 2011
P3, N=870, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
New P4 trial: Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 28, 2011
P4, N=24, Not yet recruiting, Sponsor: The Catholic University of Korea
- | Inpefa (sotagliflozin) / Lexicon Pharma
New P1 trial: A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia (clinicaltrials.gov) - Sep 22, 2011
P1, N=18, Completed, Sponsor: Lexicon Pharmaceuticals
- ||||| Lantus (insulin glargine) / Sanofi
Enrollment change, Combination therapy: Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial (clinicaltrials.gov) - Sep 19, 2011
P3, N=112, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=530 --> 112
- ||||||| Lantus (insulin glargine) / Sanofi
Trial completion, Combination therapy: Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial (clinicaltrials.gov) - Sep 19, 2011
P3, N=112, Completed, Sponsor: Sanofi
N=530 --> 112 Recruiting --> Completed
- Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Enrollment change: Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 18, 2011
P4, N=20, Completed, Sponsor: Command Hospital, India
Recruiting --> Completed N=50 --> 20
- Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Trial completion: Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 18, 2011
P4, N=20, Completed, Sponsor: Command Hospital, India
N=50 --> 20 Enrolling by invitation --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology (clinicaltrials.gov) - Aug 18, 2011
P4, N=33, Completed, Sponsor: University of Colorado, Denver
Enrolling by invitation --> Completed Recruiting --> Completed
- |||| Suiny (anagliptin) / Kowa, Suzuken
Trial completion: A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy (clinicaltrials.gov) - Aug 15, 2011
P2, N=620, Completed, Sponsor: Kowa Research Institute, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| fasiglifam (TAK-875) / Takeda
New P2 trial, Combination therapy: Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 9, 2011
P2, N=368, Completed, Sponsor: Takeda
- | Glufast (mitiglinide) / Takeda, Kissei, Januvia (sitagliptin) / Merck (MSD)
New P1 trial: Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin (clinicaltrials.gov) - Aug 9, 2011
P1, N=26, Completed, Sponsor: Samsung Medical Center